Treatment of bone disorders in renal diseases

Aim, To study possible correction of bone disorders (osteopenia, Ca/P-imbal ance, bone pain, limited volume of indolent movements) which are still a se rious complication associated with renal diseases and pathogenic therapy (s teroids). Materials and methods. The bone disorders were treated in 10 uremic hemodia lyzed patients (8 men, 2 women; group 1) with vitamin D-3 (calcitriol made in Russia) + rhEPO (recormon; Boehringer Mannheim), in 15 patients (15 wome n, 0 men) with lupus-nephritis (group 2) with vitamin D-3 (n = 5, group 2a) or miscalcic (Sandoz) (n = 10, group 2b), in 2 patients (2 men, 0 women) w ith glomerulonephritis (group 3) with vitamin D-3 + miacalcic. Additionally all the patients received Ca salts. In groups 2 and 3 renal function was n ormal. The duration of the treatment was 3-6 months. Results. In all the groups we obtained an analgetic effect (attenuation of bone pain and more indolent movements), improvement of life quality, dimini shed need in analgetics, elevation of serum Ca level (p > 0.05). Conclusion. Treatment of renal patients with bone affection with vitamin D- 3 and miacalcic has an analgetic effect, improves life quality.